Chen Jun-Xing, Deng Nan, Chen Xu, Chen Ling-Wu, Qiu Shao-Peng, Li Xiao-Fei, Li Jia-Ping
Department of Urology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Asian Pac J Cancer Prev. 2012;13(5):2229-34. doi: 10.7314/apjcp.2012.13.5.2229.
To assess efficacy of Ki67 combined with VEGF as a molecular grading model to predict outcomes with non-muscle invasive bladder cancer (NMIBC).
72 NMIBC patients who underwent transurethral resection (TUR) followed by routine intravesical instillations were retrospectively analyzed in this study. Univariate and multivariate analyses were performed to confirm the prognostic values of the Ki67 labeling index (LI) and VEGF scoring for tumor recurrence and progression.
The novel molecular grading model for NMIBC contained three molecular grades including mG1 (Ki67 LI≤25%, VEGF scoring≤8), mG2 (Ki67 LI>25%, VEGF scoring≤8; or Ki67 LI≤25%, VEGF scoring>8), and mG3 (Ki67 LI>25%, VEGF scoring>8), which can indicate favorable, intermediate and poor prognosis, respectively.
The described novel molecular grading model utilizing Ki67 LI and VEGF scoring is helpful to effectively and accurately predict outcomes and optimize personal therapy.
评估Ki67联合血管内皮生长因子（VEGF）作为一种分子分级模型预测非肌层浸润性膀胱癌（NMIBC）预后的有效性。
本研究回顾性分析了72例接受经尿道切除术（TUR）并进行常规膀胱内灌注的NMIBC患者。进行单因素和多因素分析以确认Ki67标记指数（LI）和VEGF评分对肿瘤复发和进展的预后价值。
NMIBC的新型分子分级模型包含三个分子级别，即mG1（Ki67 LI≤25%，VEGF评分≤8）、mG2（Ki67 LI>25%，VEGF评分≤8；或Ki67 LI≤25%，VEGF评分>8）和mG3（Ki67 LI>25%，VEGF评分>8），分别提示预后良好、中等和较差。
所描述的利用Ki67 LI和VEGF评分的新型分子分级模型有助于有效且准确地预测预后并优化个体化治疗。
